logo
    • Magazine
    • Membership
    • Donate
  • Racial Justice
  • Economic Justice
    • Collections
  • Climate Justice
  • Health Justice
  • Leadership
  • CONTENT TYPES
  • Subscribe
  • Webinars
    • Upcoming Webinars
    • Complimentary Webinars
    • Premium On-Demand Webinars
  • Membership
  • Submissions

New Legal Approaches May Compel Drug Companies to Pay for Opioid Crisis

Steve Dubb
December 20, 2017
Share
Tweet
Share
Email
Print
Mpv_51, via Wikimedia Commons

December 18, 2017; Michigan Public Radio

“In Michigan, nearly 1,700 people died of overdoses from an opioid drug in 2016,” reports April van Buren for Michigan Public Radio. Rebecca Haffajee, an assistant health policy professor at the University of Michigan’s School of Public Health, along with her coauthor Stanford health law professor Michelle Mello, writes in the New England Journal of Medicine that, “The opioid epidemic has claimed more than 300,000 lives in the United States since 2000 and could claim another half million over the next decade.” The Centers for Disease Control’s preliminary estimate states that there were 64,070 deaths from drug overdoses in 2016, a 21-percent increase from 2015, with opiates and/or heroin involved in more than 70 percent of the cases.

To date, over 100 lawsuits have been filed by government agencies at the local, state, and federal level, as well as by American Indian nations, Haffajee informs Michigan Public Radio.

So far, notes van Buren, “attempts to hold manufactures and distributors accountable in court through personal injury lawsuits haven’t been all that successful.” A primary reason, indicates van Buren, is that companies can shift responsibility—for example, maybe the party at fault are the doctors who prescribed drugs they shouldn’t have authorized. Or the patients themselves may take the drugs differently than instructed. As Haffajee explains, such factors make it “really difficult to pin all of the blame on manufacturers and distributors.”

To date, settlement amounts have been exceedingly modest. “The largest so far was a $600 million federal settlement with Purdue ten years ago,” Haffajee notes. But Haffajee, van Buren reports, “is optimistic that the suits being filed by federal, state, and local governments have a good chance of getting what they need most to deal with the opioid epidemic.”

As Haffajee and Mello write, with a class action lawsuit, “the causal relationship between the companies’ business practices and the harm is assessed at the group level, with the focus on statistical associations between product use and injury. The use of class actions helped overcome tobacco companies’ defenses based on smokers’ conduct.” It did not happen quickly, but ultimately the so-called Tobacco Master Settlement Agreement “forced large tobacco firms to pay a minimum of $206 billion over 25 years.”

Sign up for our free newsletters

Subscribe to NPQ's newsletters to have our top stories delivered directly to your inbox.

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

Establishing a “class” in legal terms is not easy. One can expect drug company lawyers to argue that cases are not “similar enough” to constitute a class. But as Haffajee and Mello write, as “the population harmed by opioids grows and more information about the populations is documented, it becomes easier to identify subgroups with similar factual circumstances and legal claims.”

Additionally, there are the government suits themselves. By definition, state, federal, local, and American Indian lawsuits are not personal injury lawsuits. This, says Haffajee, could make it harder for drug companies to escape liability “because there is no doctor or patient to blame.”

The focus of these government cases is on systemic social damage rather than harm to specific individuals. The claims, Haffajee notes, center on the proposition that opioid manufacturers and distributors “have in some way debilitated our social system and we need to repair them.’”

Four possible legal lines of attack in these government cases are:

  • To highlight the “public scourge created by the opioid epidemic…by oversaturating the market with drugs and failing to implement controls against misuse and diversion, thereby creating a public nuisance.”
  • To claim deceptive marketing. “In these fraud claims,” Haffajee and Mello write,
    “governments charge that companies made false representations about their products’ addictiveness and effectiveness, all calculated to mislead the state, prescribers, and the public. This argument proved powerful in suits against tobacco companies.”
  • To allege lax monitoring of suspicious opioid orders. “The federal Controlled Substances Act requires drug suppliers to maintain effective controls against, and to notify the Drug Enforcement Agency of, potentially illegitimate orders,” Haffajee and Mello note.
  • To highlight “unjust enrichment” through unfair business practices: In these cases, the government can claim that pharma companies received unfair windfall profits. As Haffajee and Mello explain, “For opioids…government payment for excessive prescriptions under public insurance programs directly contributed to companies’ profits. Already, two large settlements have occurred in cases that included unjust enrichment claims, although pharmaceutical companies avoided admitting fault.”

To date, Haffajee and Mello concede, “opioid litigation has yet to financially dent the $13-billion-a-year opioid industry.” But, as Haffajee points out, the need for resources to address the opioid crisis is not in question: “The opioid epidemic is in the tens or hundreds of billions per year in cost to society, so we need much, much more money.”—Steve Dubb

Share
Tweet
Share
Email
Print
About the author
Steve Dubb

Steve Dubb is senior editor of economic justice at NPQ, where he writes articles (including NPQ’s Economy Remix column), moderates Remaking the Economy webinars, and works to cultivate voices from the field and help them reach a broader audience. Prior to coming to NPQ in 2017, Steve worked with cooperatives and nonprofits for over two decades, including twelve years at The Democracy Collaborative and three years as executive director of NASCO (North American Students of Cooperation). In his work, Steve has authored, co-authored, and edited numerous reports; participated in and facilitated learning cohorts; designed community building strategies; and helped build the field of community wealth building. Steve is the lead author of Building Wealth: The Asset-Based Approach to Solving Social and Economic Problems (Aspen 2005) and coauthor (with Rita Hodges) of The Road Half Traveled: University Engagement at a Crossroads, published by MSU Press in 2012. In 2016, Steve curated and authored Conversations on Community Wealth Building, a collection of interviews of community builders that Steve had conducted over the previous decade.

More about: Accountabilitydrug manufacturersNonprofit Newsopioid addictionPolicy

Become a member

Support independent journalism and knowledge creation for civil society. Become a member of Nonprofit Quarterly.

Members receive unlimited access to our archived and upcoming digital content. NPQ is the leading journal in the nonprofit sector written by social change experts. Gain access to our exclusive library of online courses led by thought leaders and educators providing contextualized information to help nonprofit practitioners make sense of changing conditions and improve infra-structure in their organizations.

Join Today
logo logo logo logo logo
See comments

Spring-2023-sidebar-subscribe
You might also like
Cancelling Student Debt Is Necessary for Racial Justice
Kitana Ananda
To Save Legal Aid, Expand Public Service Loan Forgiveness
Zoë Polk
No Justice, No Peace of Mind and Body: The Health Impacts of Housing Insecurity for Black Women
Jhumpa Bhattacharya, Maile Chand and Andrea Flynn
The Human Impact of the Global Refugee Crisis Must Be Understood—And Acted Upon
Anmol Irfan
Black Americans Need Reparations: The Fight for the CTC Highlights the Roadblocks
Jhumpa Bhattacharya and Trevor Smith
Edgar Cahn’s Second Act: Time Banking and the Return of Mutual Aid
Steve Dubb

NPQ Webinars

April 27th, 2 pm ET

Liberatory Decision-Making

How to Facilitate and Engage in Healthy Decision-making Processes

Register Now
You might also like
Cancelling Student Debt Is Necessary for Racial Justice
Kitana Ananda
To Save Legal Aid, Expand Public Service Loan Forgiveness
Zoë Polk
No Justice, No Peace of Mind and Body: The Health Impacts of...
Jhumpa Bhattacharya, Maile Chand and Andrea Flynn

Like what you see?

Subscribe to the NPQ newsletter to have our top stories delivered directly to your inbox.

See our newsletters

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

NPQ-Spring-2023-cover

Independent & in your mailbox.

Subscribe today and get a full year of NPQ for just $59.

subscribe
  • About
  • Contact
  • Advertise
  • Copyright
  • Careers

We are using cookies to give you the best experience on our website.

 

Non Profit News | Nonprofit Quarterly
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.